To The Moon

The China-related benchmark Hang Seng Index (HSI) July futures was up as much as 2.8% this morning to 25,167, outperforming Asia's developed markets 🔝Currently 2.3% higher (as of 145PM), HSI call warrants are dominating the top warrant gainers table, with gains between 29% to 67%, depending on the warrant's different effective gearing levels, while HSI put warrants are down between 25% to 80% Top warrant gainers Top warrant losers Both call and put warrants are seeing buy flows as of writing, with heavier buying seen in put warrants $HSI 21400MBePW260828(NPXW.SI)$ (https://warrants.com.sg/tools/livematrix/NPXW) and WZ6W (https://warrants.com.sg/tools/livematrix/WZ6W) 📰Bloomberg reported this morning that China Reform Holdings and China Chengton

As Singapore’s reporting season approaches, attention is shifting from market performance to earnings delivery. $Straits Times Index(STI.SI)$ reached a record high of 5,561.42 on 15 July and, and delivered a 21.2% total return through 17 July, including an 18.6% price gain. Investor participation has also strengthened alongside the market’s advance.  As of 17 July, assets under management in STI ETFs had reached S$5.5 billion, approximately double the level of a year earlier, while Singapore equity ETFs are on track to record a 17th consecutive month of combined net inflows since the Equity Market Development Programme announcements in February 2025, with cumulative net inflows of S$1.6 billion. Market Flows Highlight Diverse Participation

One share price, two completely different stories I rarely see a stock where Wall Street and the market appear to be reading entirely different scripts. Hims & Hers Health trades around $33, yet the consensus target from 13 analysts sits between $28 and $30, implying roughly 13% downside. At the bullish end, Canaccord Genuity recently lifted its target to $40. At the bearish end, one analyst believes the shares are worth just $21. That's a spread of more than 90% between the highest and lowest targets, and it tells me one thing above all else: nobody can agree what this business is actually worth. The market and Wall Street rarely disagree this dramatically. Perhaps the market still knows something analysts don't. Or perhaps investors have simply fallen in love with a compelling narrat

After last week's CPI print, inflation expectations eased slightly, while the U.S.–Iran conflict flared up again and the previously-open strait was once more suspended. That said, this kind of escalation seems to occur almost every weekend, and by the time financial markets open it is quickly shrugged off—so I would not advise anyone to be overly anxious; wait until the market opens and it will speak for itself. Faced with this kind of murky, hard-to-read news flow, the best trading approach is to consider the technical indicators alone, and then set the corresponding strategy based on those indicators. Chart: CCTV News — “U.S.–Iran clashes hit civilian facilities across several countries; Iran warns of an all-out offensive” (reported July 19, 2026) I. U.S. equity indices have flipped shor

The global tech-stock sell-off has now run for more than three weeks, and most markets have pulled back to varying degrees. Among them, the sharply-corrected Korean market has even slipped into a technical bear. So is the current decline the eve of a major reversal, or just another routine technical pullback as so often before? Beyond Korea, Japan's market may offer the more valuable reference point. The valuation debate over tech stocks (AI-related) has raged for a long time, and trying to read it from a purely fundamental angle only ends in a dialogue of the deaf. Optimists believe the AI revolution will ultimately arrive; pessimists are convinced the bursting of the bubble is only a matter of time. In truth, for a trader, who is right or wrong is not the point—the point is which moment